Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
July 2024
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study
Lancet Rheumatol 2024:S2665-9913(24)00121-8 DOI 10.1016/S2665-9913(24)00121-8 Epub ahead of print
This study by Golder, et al. showed a significant protective association of lupus low disease activity state (LLDAS) and remission against damage accrual and flare. The authors also found a threshold of 3 months sustained LLDAS or remission, and that 3 months of sustained LLDAS are attainable in the setting of a 6–12-month clinical trial.
Keywords:
June 2024
Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis
Lupus Sci Med. 2024 May 28;11(1) doi: 10.1136/lupus-2024-001156
The combination of anti-dsDNA and anti-SSA/Ro60 serotype may help to foretell the patient’s renal response to belimumab. Investigators here aimed to explore the effectiveness of belimumab on active LN, exploring predictors, including serological biomarkers, of renal response to belimumab in a real-world setting.
Keywords:
Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement
Clin Rheumatol. 2024 May 20 doi: 10.1007/s10067-024-06992-7. Epub ahead of print
This real-world combination of telitacicept and standard treatment demonstrated significant improvements in anaemia, as well as increased leukocyte and platelet levels in patients with SLE and haematological involvement. Here, investigators sought to evaluate the efficacy and safety of telitacicept in combination with standard treatment in SLE patients specifically with haematological involvement.
Keywords:
May 2024
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort
Lupus Sci Med. 2024; 11(1): e001096 DOI: 10.1136/lupus-2023-001096
SLESIS-R may help clinicians make informed decisions on the occurrence of a serious infection in the following year in SLE from four variables: age ≥60 years, previous admission for SLE, previous infection and having received a maximum dose of glucocorticoids ≥30 mg.
Belimumab Corticosteroid‑Sparing Treatment in Systemic Lupus Erythematosus: a Real‑Life Observational Study (BESST)
Rheumatol. Int. 2024 Apr 30:1–7 DOI: 10.1007/s00296-024-05589-2 https://pubmed.ncbi.nlm.nih.gov/38687385/
Belimumab confers an early and sustained corticosteroid-sparing effect after 3 months of treatment in SLE patients. This was demonstrated by a significant prednisone dose reduction that continued through months 6 and 12, and was sustained until month 24.
April 2024
Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: A systematic review and meta-analysis
Lupus Sci Med 2024;11(1):e001152 DOI 10.1136/lupus-2024-001152
Patients with SLE and LN show increased risk of CV risk factors including diabetes mellitus, hypertension and hyperlipidaemia versus patients without nephritis.
CD19 CAR T-Cell therapy in autoimmune disease - A case series with follow-up
N Engl J Med 2024;390(8):687–700 DOI 10.1056/NEJMoa2308917
In this case series by Müller, et al., eight patients who received a CD19 CAR T-cell infusion achieved Definition of Remission in SLE (DORIS) remission, Lupus Low Disease Activity State and a SLEDAI 2K score of 0 at 6 months post-infusion. Long-term follow-up through 24 months showed that SLE disease activity remained absent
in all eight patients.
Keywords:
Smith-specific regulatory T cells halt the progression of lupus nephritis
Nat Commun. 2024 Feb 6;15(1):899 DOI: 10.1038/s41467-024-45056-x
Compared with polyclonal mock-transduced regulatory T cells (Tregs), Smith(Sm)-Tregs potently suppress Sm-specific pro-inflammatory responses in vitro and suppress disease progression in a humanised mouse model of lupus nephritis.
Keywords:
Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: A multicentre, open-label, randomised controlled trial
Lancet Rheumatol 224;6(3):e168–77 DOI 10.1016/S2665-9913(23)00320-X
Mycophenolate mofetil (MMF) withdrawal was not significantly inferior to MMF maintenance through Week 60 in patients with SLE that had been treated with MMF for ≥1 year.
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two Phase 3 trials
Ann Rheum Dis 2024 DOI 10.1136/ard-2023-225445 Epub ahead of print https://pubmed.ncbi.nlm.nih.gov/38569851/
Type I IFN blockade with anifrolumab modulated multiple inflammatory pathways downstream of type I IFN signalling.